The XIENCE PRO Everolimus Eluting Coronary Stent System is indicated for improving
coronary luminal diameter in the following:

- Patients with symptomatic ischemic heart disease due to discrete
de novo
native
coronary artery lesions.

- For restoring coronary flow in patients experiencing acute myocardial infarction who
present within 12 hours of symptom onset.

- For the treatment of patients with concomitant diabetes, acute coronary syndr
ome,
dual vessel lesions (two lesions in two different epicardial vessels), lesions residing
within small coronary vessels; lesions where treatment results in the jailing of side
branches (lesions with a side branch < 2 mm in diameter or an ostial stenosis
< 50%); for the treatment of elderly patients (age ≥ 65), and for treatment of both
men and women.

- For the treatment of patients presenting with in-stent restenosis in coronary artery
lesions; chr
onic total occluded coronary artery lesions (defined as coronary artery
lesions with TIMI flow 0 and lasting longer than 3 months); and coronary artery
bifurcation lesions.

Transport from Warsaw within 7 days. Please contact for more details.